Schizophrenia

New trials reveal xanomeline and trospium effectively alleviate schizophrenia symptoms, offering a novel treatment option with minimal adverse effects.

Reducing stigma, improving mental health benefits, and addressing workload concerns all need to happen simultaneously.

Schizophrenia is a chronic mental illness that significantly affects patients through its symptoms, associated health conditions, and treatment challenges, with long-acting injectable antipsychotics offering potential benefits in improving adherence and reducing relapses.

The move is expected to expand clozapine access for patients with schizophrenia.

In the phase 3 CONNEX clinical trial program, iclepertin did not meet its primary and secondary end points.

The addition of samidorphan can support the antipsychotic efficacy of olanzapine while mitigating associated weight gain.

In the trial, lumateperone had a significantly longer time to relapse in patients treated compared to placebo.

Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.

Xanomeline and trospium chloride is the first in a new class, offering a new approach with selectively targeting M1 and M4 receptors.

Paliperidone palmitate (Erzofi; Luye Pharma Group) is approved as a monotherapy for schizophrenia and as an adjunct for schizoaffective disorder.

Vitamin D deficiency (VDD) is an important factor in the pathogens of schizophrenia.

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Health care professionals providing care to patients using second-generation antipsychotics could benefit from incorporating community pharmacists as members of their team.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Pharmacists can educate patients on current clinical evidence of cannabis’s therapeutic benefit, as well as cannabis’s complexities, risks, and potential adverse effects.

Investigators suggested that this difference is caused by a common medication for treatment-resistant schizophrenia.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

Pharmacists working with patients with mental health conditions are able to optimize medication use and improve adherence.

Evidence shows vitamin D deficiency is linked to abnormal dopamine signaling disorders in neurodevelopment, including schizophrenia.

Pharmacogenomics is gaining support in mental health and polypharmacy, where the data make a strong case for improvements in clinical and economic outcomes.

The ease of administration with new agents for schizophrenia via an injection is advantageous because this patient population is commonly agitated and difficult to administer oral medications to.

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

The estimated cost burden of schizophrenia is more than $150 billion, consisting of direct treatment cost and lost productivity.